Home・Stock List・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Open

1.19 17.82

Buy Sell

Overview

Share price change

24h

Current

Min

1.01

Max

1.24

Key metrics
By Trading Economics
Income	33M 28M
Sales	35M 35M
P/E Sector Avg	2.914 56.659
EPS	0.89
Profit margin	79.717
Employees	27
EBITDA	33M 28M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+239.81% upside

Dividends
By Acuity
Next Earnings	12 Nov 2026

Market Stats
By TradingEconomics
Market Cap	6.5M 32M
Previous open	-16.63
Previous close	1.19

Actinium Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

7 Sept 2026, 23:51 UTC

Australia's Consumer Confidence Index set for release amid mixed market sentiment and rising interest rate concerns.

7 Sept 2026, 23:51 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, amid cautious optimism in the stock market despite global economic uncertainties.

7 Sept 2026, 23:51 UTC

UK Retail Sales Growth Slows to 0.5% YoY, Falling Short of Expectations Amid Consumer Caution

7 Sept 2026, 23:51 UTC

U.S. Initial Jobless Claims Expected at 205,000 Amid Strong Labor Market and Anticipated Fed Rate Hikes

7 Sept 2026, 23:51 UTC

China's Producer Prices Index Expected to Rise 3.7% Amid Mixed Economic Signals Ahead of September Release

7 Sept 2026, 23:41 UTC

Japan's Q2 2026 GDP Growth Rate Expected at 0.4% Amid Optimistic Economic Sentiment and Rising Nikkei Index

7 Sept 2026, 23:41 UTC

Japan's Q2 2026 GDP Growth Expected at +1.1% Amid Positive Economic Trends and Optimistic Market Sentiment

7 Sept 2026, 23:41 UTC

Japan's Current Account Expected at JPY 2,870 Billion Amid Positive Economic Sentiment and Speculation of Interest Rate Hikes.

7 Sept 2026, 23:31 UTC

ECB President Lagarde's Upcoming Speech Sparks Market Anticipation for Rate Hike Amid Rising Inflation and Geopolitical Tensions.

7 Sept 2026, 23:21 UTC

U.S. Core Inflation Rate Expected to Rise to 2.4% YoY Amid Strong Jobs Data, Heightening Speculation on Fed Interest Rate Hikes

7 Sept 2026, 23:21 UTC

Core Inflation Rate Release on September 11, 2026, Expected to Influence Fed's Interest Rate Decisions Amid Rising Geopolitical Tensions and Oil Prices.

7 Sept 2026, 23:21 UTC

Investors Brace for CPI Release Amid Rising Inflation Concerns and Fed Rate Hike Speculation on September 11, 2026.

7 Sept 2026, 23:21 UTC

U.S. Inflation Rate Expected to Rise 0.4% in August Amid Concerns of Federal Reserve Interest Rate Hikes Following Strong Job Growth

7 Sept 2026, 23:21 UTC

U.S. CPI Report on September 11, 2026 Expected to Show Inflation Rise Amid Market Caution and Fed Rate Hike Speculation

7 Sept 2026, 23:21 UTC

U.S. Inflation Rate Expected to Rise 3.4% YoY, Heightening Fed Rate Hike Speculations Amid Geopolitical Tensions and Oil Price Surge

7 Sept 2026, 23:11 UTC

U.S. Core Producer Prices Expected to Rise 0.3% in August Amid Geopolitical Tensions and Inflation Concerns

7 Sept 2026, 23:01 UTC

U.S. Producer Price Inflation (PPI) MoM for August set to release on September 10, with a forecasted rise of 0.4% amid inflation concerns and potential Fed interest rate hikes due to geopolitical tensions affecting oil prices.

7 Sept 2026, 23:01 UTC

NZD/JPY is lower today amid broader market volatility and geopolitical tensions following U.S. military actions against Iranian tankers. The pair remains near its one-month low.

7 Sept 2026, 23:01 UTC

Correlated Moves

AUD/JPY is trading lower, continuing a decline since Friday's close amid geopolitical tensions affecting investor sentiment and energy supply concerns.

7 Sept 2026, 23:01 UTC

Correlated Moves

GBP/JPY is declining amid heightened market volatility from geopolitical tensions and U.S. military actions, continuing lower since Friday's close.

7 Sept 2026, 23:01 UTC

Correlated Moves

CAD/JPY is declining, continuing a downward trend since Friday's close, influenced by geopolitical tensions and market volatility. The pair trades below its 20-day moving average.

7 Sept 2026, 23:01 UTC

Macro News

The USD/JPY currency pair is trading lower as the yen strengthens amid global economic uncertainties and tensions in the Middle East.

7 Sept 2026, 23:01 UTC

Correlated Moves

The EUR/JPY is lower today amid rising geopolitical tensions and a drop in USD/JPY. The exchange rate remains below its 20-day moving average.

7 Sept 2026, 23:01 UTC

Correlated Moves

CHF/JPY is trading lower as geopolitical tensions influence market sentiment, following a notable decline earlier in the session. The pair remains below its 20-day moving average.

7 Sept 2026, 22:51 UTC

Markets Anticipate ECB Deposit Facility Rate Hike Amid Rising Inflation and Geopolitical Tensions Ahead of September 10 Meeting.

7 Sept 2026, 22:21 UTC

India's Inflation Rate Release on September 14, 2026, Sparks Caution Amid Geopolitical Tensions and Rising Costs.

7 Sept 2026, 22:11 UTC

Mexico's Inflation Rate YoY for August 2026 set to release on September 9, with a forecast of 3.30% amid rising global oil prices and geopolitical tensions.

7 Sept 2026, 22:11 UTC

Mexico's Inflation Rate Expected to Rise 0.25% in August Amid Global Economic Pressures and U.S. Interest Rate Concerns.

7 Sept 2026, 22:01 UTC

MBA 30-Year Mortgage Rate Release on September 9, Amid Rising Rates and Anticipated Fed Hikes Influenced by Inflation Concerns.

7 Sept 2026, 21:51 UTC

Brazil's Central Bank to Announce Interest Rate Decision Amid Global Economic Uncertainty on September 8, 2026.

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

239.81% upside

12 Months Forecast

Average 3.5 USD 239.81%

High 4 USD

Low 3 USD

Based on 2 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Actinium Pharmaceuticals Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.